Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Sofebuvir is a prodrug that can be metabolized into the active antiviral drug 2' -deoxy-2 '-α -fluorine -β -C-methyluridine 5' -monophosphate. Currently, it is in phase 3 clinical trials for the treatment of hepatitis C. Studies have shown that sofibuvir is a nucleotide inhibitor of hepatitis C virus and has a selective inhibitory effect on HCV NS5B polymerase.